Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vasoactive Peptides in Portal Pressure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Bayside Health.
Recruitment status was:  Recruiting
Information provided by:
Bayside Health Identifier:
First received: September 13, 2005
Last updated: July 25, 2007
Last verified: September 2005
This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition Intervention
Portal Hypertension
Drug: Norfloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Bayside Health:


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • HVPG >= 12 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00163982

Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327

Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP    92762000 ext 3327   
Sponsors and Collaborators
Bayside Health
Principal Investigator: William W Kemp, MBBS, FRACP The Alfred
  More Information Identifier: NCT00163982     History of Changes
Other Study ID Numbers: AH4204
Study First Received: September 13, 2005
Last Updated: July 25, 2007

Keywords provided by Bayside Health:
HVPG > 12 mmHg

Additional relevant MeSH terms:
Hypertension, Portal
Liver Diseases
Digestive System Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on May 25, 2017